A Phase 1 interventional study of ARD-885 Tablets and ARD-885 Placebo Tablet in Rheumatoid Arthritis (RA), sponsored by Artivila (Shenzhen) Innovation Center, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by Artivila (Shenzhen) Innovation Center, Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 129th largest by enrollment of the 217 interventional ones that give a count, is one of 10 that started in 2024, is one of 54 in phase 1, and was the 226th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in China, United States, Belgium and 8 more countries
Ages 18–65
Peking University People's Hospital · Sites in China
Ages 18+
Jacobio Pharmaceuticals Co., Ltd. · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 46 · Phase 3 52 · Phase 4 28
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is close to the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 134 across the 217 interventional studies, 287 across the 32 observational. Of the 115 that completed or were terminated, 28 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 249 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Artivila (Shenzhen) Innovation Center, Ltd as lead sponsor.
Artivila (Shenzhen) Innovation Center, Ltd has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06887127Phase 3Hangzhou Highlightll Pharmaceutical Co., LtdA Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis | 2026-12-31 |
| NCT07408024Toll Biotech Co. Ltd. (Beijing)Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis | 2026-12 |
| NCT07045896Peking University People's HospitalFucoidan in the Treatment of Active Rheumatoid Arthritis | 2026-12 |
| NCT06945666Jie ChangA Study of Iguratimod in Combination With Tofacitinib in RA Patients | 2027-01-31 |
| NCT07491016Zhejiang Provincial People's HospitalEfficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis | 2027-03-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 249 studies in Arthritis, Rheumatoid with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study is a randomized, double-blind, placebo-controlled single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetic, and food effects of ARD-885 Film-coated Tablets in healthy subjects.The entire study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study in healthy subjects.
The whole study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study. The SAD and MAD studies are randomized, double-blinded, and placebo-controlled studies, and the FE study is a randomized, open-label, two-period, two-treatment (2×2) crossover study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARD-885 Tablets, 25 mg/50 mg/100 mg, once a day(QD), from Day1\~Day7
Drug: ARD-885 Tablets
ARD-885 Tablets, 5/10/30/60/100/150/200/250 mg,a single dose on Day1
Drug: ARD-885 Tablets
ARD-885 Placebo tablet, a single dose on Day1
Drug: ARD-885 Placebo Tablet
ARD-885 tablets, 50mg, a single dose on Day1 and Day7, fed or fasted crossover
Drug: ARD-885 Tablets
ARD-885 Placebo tablets, once a day(QD), from Day1\~Day7
Drug: ARD-885 Placebo Tablet
ARD-885 Tablet is a dual-target inhibitor of IRAK4 and IRAK1.
Placebo Tablet to ARD-885 tablets.
Adverse Events (AE)/Severe Adverse Events (SAE)
Safety and tolerability are assessed by the incidence of adverse events and its severity caused by the study drug during or after dose.
Time frame: The first day of the first administration until 7 days after the last administration.
PK: Cmax of ARD-885.
Pharmacokinetics (PK): Maximum observed concentration.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: T1/2 of ARD-885.
Pharmacokinetics (PK): Apparent terminal elimination half-life.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: Tmax of ARD-885.
Pharmacokinetics (PK): Time to reach Cmax. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: AUC0-t of ARD-885.
Pharmacokinetics (PK): The area under the plasma concentration-time curve from time 0 to concentration time.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: AUC0-last of ARD-885.
Pharmacokinetics (PK): The area under the plasma concentration-time curve, from time 0 to the last measurable non-zero concentration.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: AUC0-inf of ARD-885.
Pharmacokinetics (PK): The area under the plasma concentration-time curve from time 0 extrapolated to infinity.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: CL/F of ARD-885.
Pharmacokinetics (PK): Apparent oral drug clearance.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: Css_max of ARD-885.
Pharmacokinetics (PK): Steady-state maximum blood concentration in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: Css_min of ARD-885.
Pharmacokinetics (PK): Steady-state minimum blood concentration in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: Tss_max of ARD-885.
Pharmacokinetics (PK): Time to reach Cmax at steady state in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: AUCss_tau of ARD-885.
Pharmacokinetics (PK): The area under the concentration-time curve at one dosing interval after reaching a steady state in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: RACmax of ARD-885.
Pharmacokinetics (PK): Accumulation ratio on Cmax of ARD-885 in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PK: RAAUCtau of ARD-885
Pharmacokinetics (PK): Accumulation ratio on AUCtau in MAD study.
Time frame: Pharmacokinetics blood samples were collected from Day1 before administration to 48 hours after the last administration.
PD: The concentration of TNF-α
TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.
Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.
PD: The concentration of IL-6.
TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.
Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.
PD: The concentration of IL-1β.
TNF-α, IL-1β and IL-6 are a pro-inflammatory cytokines whose high expression indicating the activation of TLRs/IL-1R/NF-κB signaling pathway. Healthy Subjects in MAD study(B1\~B3) will have their blood samples collected to detect levels of inflammatory factors TNF-α, IL-1β and IL-6 expression.
Time frame: blood samples were collected from 1 hour before first administration to 24 hours after the last administration.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2024 to primary completion in Aug 2025, 7 months.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 7 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.